



Tuberculosis Vaccines for Domestic and Wildlife Species

Guest Editor:

Prof. Dr. Javier Bezos

Animal Health Department of
Veterinary Faculty and VISAVET,
Universidad Complutense de
Madrid, 28040 Madrid, Spain

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

Tuberculosis is a zoonotic disease with a significant impact in Animal and Public Health. Regarding the absence of an effective vaccine to prevent the infection, the BCG vaccine is the only commercially available vaccine for humans and it has been used also in animals, showing in general a limited performance preventing the infection although reducing the severity of lesions. Other vaccines have been developed in recent years or are currently under development and some of them have been evaluated in animals with promising results. An effective immunization against tuberculosis in animals would be of paramount importance to achieve the eradication of zoonotic tuberculosis and thus achieve the objective of eradicating human tuberculosis set by the WHO for the year 2050.

In this special issue is open to include original research manuscripts related to the development and evaluation of vaccines and strategies of immunization against tuberculosis in domestic and wildlife species that contribute to increasing knowledge in this field, favoring the control and eradication of tuberculosis in the future.

Prof. Dr. Javier Bezos

Guest Editor





Editor-in-Chief

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)